More than 40 years after these initial reports, CA125 is an FDA-approved biomarker to monitor the progression and recurrence of ovarian cancer and remains the gold standard biomarker for the clinical management of ovarian cancer [3]. Here, MUC16 is linked to ovarian carcinoma.